Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer

Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer

Immune checkpoints are intensively investigated as targets in cancer therapy. T-cell immunoreceptor with immunoglobulin (Ig) and ITIM domains (TIGIT) and its ligand poliovirus receptor (PVR) are recently emerging as novel promising targets in immunotherapy. Here, we show that high expression of PVR...

Full description

Bibliographic Details
Main Authors: Hauke Stamm, Leticia Oliveira-Ferrer, Eva-Maria Grossjohann, Jana Muschhammer, Vanessa Thaden, Franziska Brauneck, Roman Kischel, Volkmar Müller, Carsten Bokemeyer, Walter Fiedler, Jasmin Wellbrock
Format: Article
Language:English
Published: Taylor & Francis Group 2019-12-01
Series:OncoImmunology
Subjects:
tigit
pvr
immunotherapy
breast cancer
Online Access:http://dx.doi.org/10.1080/2162402X.2019.1674605

Internet

http://dx.doi.org/10.1080/2162402X.2019.1674605

Similar Items